natgillin/translations-raw huggingface dataset:
The method according to claim 1, wherein the mineral impurities are selected from varying amounts of dolomite and silica-containing rocks or minerals, silica in the form of flint or quartz, feldspars, amphibolites, mica schists and pegmatite, as disseminations, nodules, layers within the calcium carbonate rock, or as side rocks. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da su mineralne nečistoće odabrane iz skupine koja sadrži različite količine stijena ili minerala koji sadrže dolomit i silicij, kao silicij u obliku kremena ili kvarca, fcldspata, amfibola, liskun škriljavca i pcgmatita, kao rasijani, nodularni, slojevi unutar stijenc od kalcijevog karbonata ili kao sporedne stijene.
Further aspects of the invention include: 
Datum objave europske prijave patenta:
• is free of surfactants, with the exception of polysorbate 80. 
ne sadrži surfaktante, s izuzetkom polisorbata 80.
Crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate obtainable by the process of any of claims 9 to 12, wherein the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate is substantially pure. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 38 do 43, naznačena time što se kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion pripravlja za oralnu, parenteralnu, nazalnu, topikalnu ili sublingvalnu primijenu.
or a N-oxide, or a pharmaceutically acceptable salt or a solvate thereof. 
ili N-oksid, ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
The rod 3, thus separated from the body 2, is inserted in the ground adjacent to the plant that has just been grafted, thus acting as a signal for the worker that the grafting procedure has finished. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time, da se šipka (3), nakon odvajanja od navedenog tijela (2), postavlja tako da podupire presađenu biljku.
The compound of Formula (1), the pharmaceutically acceptable salt thereof, or the solvate thereof of claim 1, wherein the compound of Formula (I) is any one of the following compounds: 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol iz patentnog zahtjeva 1, gdje je spoj formule (1) bilo koji od sljedećih spojeva: x A e SI, s
a concentration of phenylephrine between 0.2 and 0.4%. 
- < koncentracija fenilefrina, kao simpatomimetičko sredstvo između 0,2 i 0,4%;
For example, a series of protuberances may replace or augment the sleeve 18 . 
Naprimjer, niz ispupčenja može zamijeniti ili povećati košuljicu 18.
A capsule for preparing a beverage by injection of a fluid, comprising a closed chamber and a means for allowing the said beverage to flow out, the closed chamber of said capsule comprising ground green coffee beans that has been heat treated at a temperature between 100°C and 180°C for at least 5 minutes, keeping the moisture level between 6% and 20% of the total weight of the coffee beans, wherein the green coffee beans have not been subjected to roasting. 
Kapsula za pripravu napitaka injiciranjem tekućine, koja sadrži zatvorenu komoru i napravu koja omogućuje istjecanje navedenog napitka, gdje zatvorena komora navedene kapsule sadrži mljevena sirova zrna kave, toplinski obrađena na temperaturi između 100 *C 1 180 C u trajanju od najmanje 5 minuta, uz održavanje razine vlage između 6% 120% od ukupne težine zrna kave, naznačena time što sirova zrna kave nisu podvrgnuta prženju.
An isolated monoclonal antibody, or an antigen binding fragment thereof, comprising a heavy chain variable region having at least 95% sequence identity to SEQ ID NO: 7, 23, 39, 51, 67, 79, 96, 108, 114, 121, 137, 151, 165, 179, 187, 201, 210, 218, 227, 241, 253, 257, 273, 277, or 281, wherein said antibody binds to human C5 protein. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema zahtjevu 1, naznačen/o time, da obuhvaća varijabilno područje jakog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:7; i varijabilno područje slabog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:8.
film coating the tablet from the step (6). 
oblaganja filmom tableta iz koraka (7).
Such ultrafiltration may e.g. be performed on ultrafiltration media excluding components having molecular weights below 5 kDa. 
Takva ultrafiltracija može se primijeniti s pomoću medija za ultrafiltraciju koji eliminira komponente koji imaju molekularnu masu ispod 5 kDa.
The pharmaceutical composition of claim 1, comprising an effective amount of the compound of the structure: wherein the pharmaceutical composition is in the form of a liquid dosage form. 
16. Farmaceutski sastav koji sadrži učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva od 1 do 14.ili njegovu
A recombinant antibody molecule, or an a4-binding fragment thereof, comprising a variable heavy chain and a variable light chain, wherein: 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, naznačena time, da obuhvaća varijabilni jaki lanac i varijabilni slabi lanac, pri čemu:
Amides of the formula X can be prepared by coupling of the corresponding 2-mercapto-benzamides (synthesised by reduction of the corresponding 2,2′-dithiobenzamides analogous to those described in e.g. Elworthy, T. R.; Ford, A. P. D. W.; Bantle, G. W.; Morgans, D. J.; Ozer, R. S.;et al. J. Med. 
Amidi formule X mogu sc pripremiti vezanjem odgovarajućeg 2-merkapto-benzamida (sintetiziranog redukcijom odgovarajućeg 2,2-ditiobenzamida analogno metodi opisanoj u npr. Elworthy, T.R; Ford, A.P.O.W.; Bantle, G.W.; Morgans, D.J.: Ozer.
cooling the solution resulting from step (iii) to a temperature of about 10° C.; adjusting the solution resulting from step (iii) to a protein concentration of about 5.7%, adjusting pH value to about 5.7 by addition of an aqueous solution of lactic acid, and adding NaCl to a concentration of about 1.9%; and 
(111) hlađenje otopine dobivene u koraku (11) do temperature od 10%C; (iv) podešavanje otopine dobivene u koraku (iii) do koncentracije proteina od 5.7% 1 pH vrijednosti od 5.7 putem dodavanja vodene otopine mliječne kiseline i dodavanja NaC1 do koncentracije od 1.9%;
The valve assembly (5) according to claim 1, arranged for receiving and shearing, through a rotation run of the rotating stopper (54), a pipe (9) of a production or drilling line selected from the following group: 
Ventilni sklop (5) u skladu s patentnim zahtjevom 1, naznačen time što služi za prihvaćanje i siječenje, zakretanjem rotirajućeg zatvarača (54), cijevi (9) proizvodne ili bušaće linije koju se bira 1z sljedeće skupine:
at least one active agent; and wherein the extended release matrix formulation when subjected to an indentation test has a "penetration depth to crack distance" of at least about 1.0 mm. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, naznačen time da formulacija matrice s produljenim otpuštanjem kada je podvrgnuta indentacijskom testu ima „dubinu prodiranja s razmakom pukotine“ od barem oko 1.0 mm.
A beverage dispensing assembly according to claim 10, characterized in that the resilient support means (18) are provided in the base unit (3) extending axially downward therefrom. 
Sklop za točenje pića prema zahtjevu 10, naznačen time, da su elastična potporna sredstva (18) predviđena u osnovnoj jedinici (3) i ta se sredstva protežu od nje aksijalno prema dolje.
The medicament for use according to any one of claims 1, 3 or 4, wherein the medicament is a pharmaceutical composition in the form of a sterile solution. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema patentnom zahtjevu 1, naznačen time, da smanjuje atrofiju mozga.
The method of any preceding claim, wherein up to one of the possible media items is selected for output based on previous output of at least one of the possible media items by the receiver (1). 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se najviše jednu od mogućih medijskih točaka bira za izlaženje na osnovi prethodnog izlaženja najmanje jedne od mogućih medijskih točaka od strane prijemnika (1).
The method according to any of the preceding claims, wherein the protective overlay (1) is powder based and wherein the resin and the wear resistant particles of the protective powder based overlay (1) comprise a melamine formaldehyde resin and aluminum oxide, respectively. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što se zaštitni sloj prevlake (1) temelji na prahu i pri čemu smola i čestice otporne na habanje zaštitnog sloja prevlake temeljenog na prahu (1) redom sadrže melaminsku formaldehidnu smolu i aluminijev oksid.
A pharmaceutical comprising the 1-thio-D-glucitol compound, the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt according to any one of claims 1 to 17, in combination with at least one pharmaceutical selected from the group consisting of an insulin sensitizing agent, which is selected from the group consisting of a PPAR-Y agonist, a PPAR-a/Y agonist, a PPAR-δ agonist and a PPAR-a/Y/δ agonist; a glycosidase inhibitor; a biguanide; an insulin secretion accelerator; an insulin preparation; and a dipeptidyl peptidase IV inhibitor. 
Farmaceutski pripravak prema zahtjevu 21, naznačen time da nadalje sadrži najmanje jedno sredstvo za senzibilizaciju inzulina, koje je odabrano iz skupine koja sadrži PPAR-Y agonist, PPAR-a/Y agonist, PPAR-δ agonist i PPAR-a/Y/δ agonist; inhibitor glukozidaze; bigvanid; akcelerator sekrecije inzulina; pripravak inzulina; i inhibitor dipeptidil peptidaze IV.
9-15% of total mass 
9-15% ukupne mase
Example 5: Crystallization of batch C3 (orthorhombic polymorph) 
Primjer S: Kristalizacija serije C3 (ortorombski polimorf)
Combination of R,R-glycopyrrolate, formoterol and a glucocorticoid selected from budesonide and mometasone or their physiologically acceptable salts for use in the treatment of inflammatory diseases. 
Kombinacija R.R-glikopirolata roliprama i budesonida ili njihovih fiziološki prihvatljivih soli, naznačena time, da se koristi za liječenje upalnih oboljenja.
As an example, compositions might consist essentially of artemether or arteether and a pharmaceutically acceptable excipient consisting essentially of a triglyceride, liquid at 37°C, and medium chain triglycerides (as defined herein). Particularly preferred compositions of the invention consist essentially of: artemether or arteether, and one or more pharmaceutically-acceptable excipients selected from the group consisting of: medium chain length triglycerides; short chain triglycerides; and omega-3-marine triglycerides, said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
Kompozicija prema patentnom zahtjevu 1 naznačena time što se uglavnom sastoji od: artemetra ili arteetra; i jednog ili više farmaceutski prihvatljivih inertnih punitelja izabranih iz grupe koju čine: triglideridi srednje dužine lanca; trigliceridi kratkog lanca; omega-3 trigliceridi porijeklom iz mora; i riblje ulje, bogato omega-3-kiselinama pri čemu je navedena kompozicija formulirana za transmukozalnu subligvalnu, bukalnu ili nazalnu dozu.
Treatment and Prevention of The Diseases of the Invention 
Datum podnošenja europske prijave patenta:
24a. In another embodiment the invention is a pharmaceutical composition for use according to statement 22a or 23a, wherein said tumor diseases are solid tumors, preferably epithelial tumors, such as prostate carcinoma; mammary carcinoma; pancreatic carcinoma; lung carcinoma; gastrointestinal tract carcinoma, such as colon carcinoma; kidney cancer; thyroid carcinoma; uterine carcinoma; adrenal carcinoma. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 17 ili 18, naznačen time što su navedene tumorske bolesti čvrsti tumori, po mogućnosti tumori epitela, poput karcinoma prostate; karcinoma dojke; karcinoma gušterače; karcinoma pluća; karcinoma gastrointestinalnog sustava, poput karcinoma debelog crijeva; raka bubrega; karcinoma štitnjače; karcinoma maternice; karcinoma nadbubrežne žlijezde.
placing at least one geocell upon the first granular layer; 
postavljanje barem jedne geoćelije (82) na prvi sloj granulata (70);
F is fluoro or 18fluoro; or to a pharmaceutically acceptable acid addition salt. 
F je fluor ili "fluor; ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
Intermediate (2) 2,4-Dichloro-3-bromomethyl-benzenesulfonyl chloride ml of chlorosulfonic acid are dropwise added with 4.8 ml of 2,6-dichlorotoluene in two hours, under magnetic stirring at room temperature. 
Međuprodukt (2) 2,4-Diklor-3-bromometil-benzensulfonil klorid 10 mL klorsulfonske kiseline je dokapano u 4.8 mL 2,6-diklortoluena kroz dva sata uz magnetsko miješanje pri sobnoj temperaturi.
combining bulk aripiprazole and a vehicle to form a primary suspension; 
miješanje rasutog aripiprazola i nosača da nastane primarna suspenzija;
The device according to claim 11, wherein the outlet for removing the torrefied material is connected to a cooling chamber, and wherein the torrefied material can be introduced from the torrefying chamber into the cooling chamber. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 9-14, naznačen time što izlaz (13) je povezan s komorom za hlađenje (40), te time što se torificirani materijal može dovesti iz komore za torefakciju (55) u komoru za hlađenje
This sandwiched position of the rim portion of the capsule prevents a delamination of the foil member 5 from the base body 4 of the capsule 1. 
Taj položaj stisnutog sendviča predjela ruba čahure sprečava razdvajanje sloja elementa koji je načinjen od folije 5 od osnovnog tijela 4 čahure 1.
Preferably, the fuel is provided with one or more longitudinally extending holes, such as holes 11 in Figures 1 through 5. 
Poželjno je gorivo osigurano sa jednim ili više otvora koji se protežu uzdužno, kao što su otvori 11 na slikama 1 do 5.
converting a compound of Formula XLI to a compound of Formula XLII by reaction with a Wittig reagent; 
konverziju spoja Formule XLI u spoj Formule XLII reakcijom s Wittigovim reagensom:
The method as claimed in claim 16, wherein the fresh response includes a false address to cause the message to be sent to a smart services control node, and wherein said node is the message controller or a different network element such as a different message controller. The method as claimed in claim 16, wherein the fresh response includes a false address to cause the message to be sent to a smart services control node, and wherein the node is one of a plurality of message controllers which is dynamically selected. 
Postupak prema bilo kojem od zahtjeva 10 do 13, pri čemu novi odgovor sadrži lažnu adresu kako bi se dovelo do toga da se poruka pošalje ka kontrolnom čvoru za pametne servise i pri čemu je navedeni čvor kontroler poruka ili neki različiti mrežni element, kao što je neki drugi kontroler poruka, i/ili pri čemu je čvor jedan od većeg broja kontrolera poruka koji se dinamički odabira.
an additional solvent; 
dodatno otapalo;
Elution is carried out preferably at pH 8.4±0.1, e.g. 
Elucija se provodi kod pH 8.4 + 0.1 1j.
“C1-C12-alkyl” refers to alkyl groups having 1 to 12 carbon atoms. 
"C;,-C;2-alkil" odnosi se na alkilnu skupinu s 1 do 12 atoma ugljika.
the heterologous polynucleotide is a codon-optimized NDV-F VIId polynucleotide, the promoter is a SV40 promoter and the polyadenylation signal is SEQ ID NO: 13, further wherein the heterologous polynucleotide encoding NDV-F is inserted into the region between ORF UL55 and ORF LORF5 in the unique long (UL) region of the Gallid herpesvirus 3 (MDV-2) SB-1 strain vector; or 
Pripravak ili cjepivo, naznačen/o time, da obuhvaća rekombinantni vektor herpesvirusa purana (HVT – engl. herpesvirus of turkey), pri čemu HVT vektor nadalje obuhvaća ili: NDV-F-gen koji ima polinukleotidnu sekvencu prikazanu u SEQ ID BR:1, koji je operativno povezan s SV40 promotorom i SV40 poliA-signalom, i umetnut je u IG1 lokus od HVT genoma; ili
Those of skill in the treatment of disorders or conditions mediated by glycogen phosphorylase could easily determine the effective daily amount from the test results presented hereinafter and other information. 
Oni koji su stručni u liječenju poremećaja ili stanja posredovanih glikogen-fosforilazom mogu lako odrediti učinkovitu dnevnu količinu iz ispitnih rezultata koji su ovdje prezentirani te drugih informacija.
The method of claim 16 wherein the second fluid is injected into the sloped chute upstream of the propulsion gas along the sloped chute. 
Postupak prema zahtjevu 11 naznačen time što se drugi fluid ubrizgava u nagnuti kanal uzvodno ili nizvodno od pogonskog plina uzduž nagnutog kanala.
R is a moiety comprising at least one functional group selected from the group consisting of a double bond, halo, cyano, hydroxy, sulfonyl, aldehyde, carbonyl, carboxy, ether, ester, carboxamide, amine, hydrazinyl, ammonium, azide and 5- or 6-membered heterocyclic group with the proviso that R is not allyl; 
R je vrsta koja obuhvaća barem jednu funkcionalnu skupinu izabranu iz grupe koja obuhvaća halo, cijano, hidroksil, sulfonil, aldehid, karbonil, karboksil, eter, ester, karboksamid, amin, hidrazinil, amonij, azid i 5- ili 6-eročlanu heterocikličku skupinu;
talc, wherein the talc is present in an amount of 12.5 mg; silicon dioxide, wherein the silicon dioxide is present in an amount of 2.88 mg; and 
talk, pri čemu je talk prisutan u količini od 12,5 mg; i silicijev dioksid, pri čemu je silicijev dioksid prisutan u količini od 2,88 mg; i
The pharmaceutical composition of Claim 14, wherein the additional therapeutic agent is an AT1 receptor antagonist. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time, da je dodatno terapijsko sredstvo antagonist ATI receptora.
Forodesine in combination with Rituximab, for use according to claim 6, wherein Forodesine and Rituximab are administered concurrently or sequentially. 
7. = Forodesin u kombinaciji s rituksimabom, namijenjeni upotrebi u skladu s patentnim zahtjevom 6, naznačeni time što se forodesin i rituksimab primijenjuje istodobno ili uzastopno.
A process for the preparation of a compound of formula I according to claim 1, which comprises 
Postupak za proizvodnju spoja formule I koji se traži u zahtjevu 1, naznačen time, da obuhvaća
The method of claim 1, wherein the mother is homozygous for a first allele at the second location and the father is homozygous for a second allele at the second location, the second allele corresponding to the second sequence. 
za svakog od lokusa iz prve skupine: određivanje očinskog genoma je homozigotno za odgovarajući prvi alel; i određivanje majčinskog genoma je homozigotno za odgovarajući drugi alel.
Process according to claim any one of claims 1 to 7, wherein said process produces a biscuit having a simple sugars content of about 15% in weight per total weight. 
Postupak sukladno bilo kojem od zahtjeva 1 do 7, pri čemu se proizvode keksi sa sadržajem jednostavnih šećera otprilike 15% mase u odnosu na ukupnu masu.
For instance, the cap 1500, as shown in Figure 15, may be used for shaking out large or coarse items that are contained within the container 1500 . 
Tako se npr. poklopac 1500, kako je prikazan na Slici 15, može koristiti za istresanje velikih ili grubih predmeta koji se nalaze u posudi 1500.
1 and 3, the method comprises taking process air flowing out of the forming chamber 1 and introducing it into the forming mandrel 13, so as to cool the forming mandrel 13 . This may be done with any of the technical solutions for this purpose described with reference to the belling machine. 
Postupak oblikovanja prema zahtjevu 14 kada ovisi, izravno ili neizravno, o zahtjevu 12, naznačen time da sadrži uzimanje zraka za postupak koji istječe iz komore za oblikovanje (1) i njegovo uvođenje u rog za oblikovanje (13), kako bi se ohladio rog za oblikovanje (13).
and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatom e.g. selected from N or O, or R1 is hydroxy and R2 is formyl; 
R:iR, zajedno s atomom dušika na koji su priključeni tvore 5 do 7-člani heterociklički prsten koji sadrži barem 1 atom dušika ili 1 atom dušika i 1 dodatni heteroatom primjerice odabran od N ili O, ili R, je hidroksi i R, je formil;
It may thus be purified from any natural source or material, such as e.g. from body fluids such as urine. 
Može stoga biti pročišćen iz bilo kojeg prirodnog izvora ili materijala poput tjelesnih tekućina kao mokraća.
The black thick solution was poured under stirring into a mixture of ice and 1N HCl (800mL), then the resulting white-orange solid was filtered, and washed successively with water, saturated solution of NaHCO3 and finally with water until pH of the filtrate was 7. 
Gusta crna otopina se uz miješanje izlije u smjesu leda i IN HC1 (800 mL), te se potom nastala bijelo-narančasta krutina profiltrira i sukcesivno ispere s vodom, zasićenom otopinom NaHCO; te konačno s vodom dok pH filtrata ne bude 7.
The use according to claim 3, where dose a is within the range of from 10 to 65 wt.% of dose c and where dose b is within the range of from 35 to 90 wt.-% of dose c. 
Lijek prema patentnom zahtjevu 10, naznačen time da je doza a unutar raspona od 10 do 65 % po težini doze c i da je doza b unutar raspona od 35 do 90 % po težini doze c.
Suloctidil or a pharmaceutically acceptable derivative thereof for use according to claim 1 wherein the use is for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with the bacterial infection. 
5. < Kombinacija prema zahtjevu 1 ili zahtjevu 2 naznačena time da je za upotrebu za ubijanje klinički latentnih mikroorganizama povezanih s mikrobnom infekcijom.
(b2) mixing the lysis buffer with the bone marrow several times using a syringe, and (b3) standing the solution for 10-20 seconds; neutralizing the bone marrow lysate, comprising the sub-steps of: 
(b1) dodavanje deseterostruke količine lizatnog pufera u koštanu srž; (b2) miješanje lizatnog pufera s koštanom srži nekoliko puta uz pomoć štrcaljke; i (b3) ostavljanje otopine da odstoji u vremenu od 10 do 20 sekundi; neutraliziranje lizata koštane srži, koje sadrži svoje sljedeće korake:
Step 4:In a final step, a compound of formula (VII) is reacted with a formylating agent (VIII) to give compound (I). 
Korak 4: U završnom koraku, spoj formule (VII) reagira s formilirajućim agensom (VIII) da bi dao spoj (1).
The hydrogenation mixture was filtered, and the solvent was removed under reduced pressure. 
Hidrogenizirana smjesa se filtrira, i otapalo se ukloni pri sniženom tlaku.
The agents of the invention may be administered by any appropriate route, e.g., orally, e.g., in the form of a tablet or capsule; parenterally, e.g., intravenously; by inhalation, e.g., in the treatment of inflammatory or obstructive airways disease; intranasally, e.g., in the treatment of allergic rhinitis; topically to the skin, e.g., in the treatment of atopic dermatitis; or rectally, e.g., in the treatment of inflammatory bowel disease. 
Sredstva izuma mogu se dati bilo kojim odgovarajućim putem, npr. oralno, npr. u obliku tableta ili kapsule; parenteralno, npr. intravenski; inhalacijom, npr. u liječenju upalnih ili opstrukcijskih bolesti dišnih puteva; intranazalno, npr. u liječenju alergijskog rinitisa; površinski na kožu, npr. u liječenju atopičnog dermatitisa; ili rektalno, npr. u liječenju upalne bolesti crijeva.
The support may be, e.g., in a shape selected from the group consisting of squares, rings, discs, and cruciforms. 
Potpora može biti, primjerice u obliku koji je izabran iz skupine koja obuhvaća kvadrate, prstene, diskove te križaste oblike.
Detection at A280. 
Detekcija pri A280.
wherein R1, R2 and R6 are as defined in claim 23 . 
(Ila) pri čemu su R1, R2 1 R6 kao što su definirani u zahtjevu 8.